SYHX1903 / CSPC Pharma - LARVOL DELTA

Primary gingival diffuse large B‑cell lymphoma with muscle invasion: A case report. (PubMed, Oncol Lett) - "The patient received three lines of anti-neoplastic therapy (R-CHOP, R-CHOEP and SYHX1903) and achieved stable disease for 6 years. Due to the patient suffering from heart failure after the third line of the previous chemotherapy, palliative radiotherapy was administered to the left forearm, and the patient achieved a partial response. In conclusion, primary gingival DLBCL with muscle invasion is rare and easily misdiagnosed, and individualized treatment should be considered for these complex cases."

Journal • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Lymphoma • Mood Disorders • Non-Hodgkin’s Lymphoma • Oncology • Palliative care • BCL2 • BCL6 • CD20 • IRF4 • MYC

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov) - P1/2; N=312; Not yet recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1/2 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology

CSPC’s CDK9 inhibitor and Claudin 18.2 mAb nodded for trials in China and US respectively (GBI Health) - "China-based CSPC Pharmaceutical Group Ltd (01093.HK) announced clinical trial approvals for its CDK9 inhibitor SYHX1903 and Claudin 18.2 monoclonal antibody (mAb) NBL-015 in China and the United States respectively. SYHX1903, a highly selective CDK9 inhibitor, can now enter a clinical study in malignant hematological tumors. NBL-015...can now be assessed in solid tumors in Phase I clinical trials in the US, including for pancreatic cancer and gastroesophageal cancer."

Non-US regulatory • Esophageal Cancer • Gastric Cancer • GastroEsophageal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Pancreatic Cancer